Loading…
Akebia Therapeutics, Inc. is projected to rise to $1.25 by 2027, a +21% move from its current price of $1.03. AKBA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.9855 | $1.03 | $1.08 | +0.11% |
| May 30 | $0.9682 | $1.03 | $1.10 | +0.21% |
| May 31 | $0.9554 | $1.03 | $1.12 | +0.32% |
| Jun 1 | $0.9449 | $1.03 | $1.13 | +0.42% |
| Jun 2 | $0.9358 | $1.04 | $1.15 | +0.53% |
| Jun 3 | $0.9278 | $1.04 | $1.16 | +0.63% |
| Jun 4 | $0.9206 | $1.04 | $1.17 | +0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9206 | $1.04 | $1.17 | +0.74% |
| Week 2 | $0.8825 | $1.05 | $1.24 | +1.48% |
| Week 3 | $0.8558 | $1.05 | $1.30 | +2.23% |
| Week 4 | $0.8349 | $1.06 | $1.35 | +2.98% |
| Week 5 | $0.8177 | $1.07 | $1.40 | +3.74% |
| Week 6 | $0.8029 | $1.08 | $1.44 | +4.51% |
| Week 7 | $0.7901 | $1.08 | $1.49 | +5.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. Akebia was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc. (AKBA) is a healthcare company with a current price of $1.02 and a market capitalization of $273.62M. Its rank is 3607. The forecast suggests a gradual price recovery over time, with a 2026 average price of $1.02 and a 2027 average of $1.24, then continuing higher to $1.24 by 2030, and culminating at an average of $5.65 by 2050.
The outlook includes Neutral sentiment in 2026 and 2029, with Bullish sentiment in 2027, 2028, 2030-2035, 2040 and 2050.
A major floor 51.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.1% below — buyers have tended to step in here.
The nearest ceiling, 50.5% above — a clean break opens room to run.
A major ceiling 76.1% above — clearing it would confirm fresh momentum.
Key AKBA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKBA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.02 | Buy | $1.03 | Buy |
| MA 10 | $1.04 | Sell | $1.06 | Sell |
| MA 20 | $1.18 | Sell | $1.14 | Sell |
| MA 50 | $1.32 | Sell | $1.27 | Sell |
| MA 100 | $1.34 | Sell | $1.43 | Sell |
| MA 200 | $1.88 | Sell | $1.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.78 | Neutral |
| Stoch RSI (14) | 95.70 | Sell |
| CCI (20) | -68.38 | Neutral |
| Williams %R (14) | -52.63 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -11.21 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 47.37 | Neutral |
| TRIX (15) | -0.99 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 37.40 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 1.03 | Sell |
| ADX (14) | 23.79 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is Bearish, with RSI14 at 40. The stock is trading relative to its moving averages, with SMA50 at $1.34 and SMA200 at $1.91. Immediate support is at $0.895 and resistance at $1.56. The 30-day range runs from $0.7438 to $1.40, illustrating a tight but downward-facing short-term trajectory.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.895 | $1.03 | $1.54 | 0% | Neutral | |
| $0.9256 | $1.25 | $1.81 | +21% | Bullish | |
| $0.9131 | $1.29 | $1.98 | +25% | Bullish | |
| $0.8499 | $1.25 | $2.00 | +22% | Bullish | |
| $0.8489 | $1.30 | $2.15 | +26% | Bullish | |
| $1.12 | $1.78 | $3.03 | +73% | Bullish | |
| $1.29 | $2.11 | $3.70 | +105% | Bullish | |
| $1.34 | $2.26 | $4.05 | +119% | Bullish | |
| $1.37 | $2.39 | $4.39 | +132% | Bullish | |
| $1.24 | $2.23 | $4.17 | +116% | Bullish | |
| $1.91 | $3.94 | $8.05 | +283% | Bullish | |
| $2.76 | $6.13 | $14.11 | +496% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.895 | $1.03 | $1.23 | +0.00% |
| June 2026 | $0.9343 | $1.11 | $1.37 | +8.07% |
| July 2026 | $0.938 | $1.13 | $1.42 | +1.83% |
| August 2026 | $0.9023 | $1.10 | $1.41 | -2.73% |
| September 2026 | $0.916 | $1.13 | $1.46 | +2.47% |
| October 2026 | $0.9457 | $1.18 | $1.54 | +4.13% |
| November 2026 | $0.9231 | $1.16 | $1.53 | -1.65% |
| December 2026 | $0.9122 | $1.15 | $1.54 | -0.47% |
Click any year to see its month-by-month AKBA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akebia Therapeutics, Inc.'s 2026 outlook centres on $1.03, within a $0.895 to $1.54 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, AKBA could reach as high as $1.81, with a base case around $1.25 and support toward $0.9256 — roughly +21% from $1.03. Buyers look set to stay in control over this stretch.
Expect AKBA to range from $0.9131 to $1.98 through 2028. The $1.29 average target implies a +25% move from current prices. That is up +4% on the projected 2027 average. Momentum favours further upside here.
The AKBA price prediction for 2029 points to an average of $1.25 (low $0.8499, high $2.00) — a potential gain of +22% on today's $1.03. Buyers look set to stay in control over this stretch.
In 2030, AKBA is projected to trade between $0.8489 and $2.15, averaging $1.30 — a potential gain of +26% from today's $1.03. That is up +4% on the projected 2029 average. Momentum favours further upside here.
Akebia Therapeutics, Inc.'s 2031 outlook centres on $1.78, within a $1.12 to $3.03 range. That is up +37% on the projected 2030 average. That marks a +73% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, AKBA could reach as high as $3.70, with a base case around $2.11 and support toward $1.29 — roughly +105% from $1.03. Momentum favours further upside here.
Expect AKBA to range from $1.34 to $4.05 through 2033. The $2.26 average target implies a +119% move from current prices. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The AKBA price prediction for 2034 points to an average of $2.39 (low $1.37, high $4.39) — a potential gain of +132% on today's $1.03. Momentum favours further upside here.
In 2035, AKBA is projected to trade between $1.24 and $4.17, averaging $2.23 — a potential gain of +116% from today's $1.03. That is -7% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Akebia Therapeutics, Inc.'s 2040 outlook centres on $3.94, within a $1.91 to $8.05 range. That is up +77% on the projected 2035 average. That marks a +283% change versus current levels. Momentum favours further upside here.
By 2050, AKBA could reach as high as $14.11, with a base case around $6.13 and support toward $2.76 — roughly +496% from $1.03. Buyers look set to stay in control over this stretch.
Investing $1,000 in AKBA today (≈ 970.873786 AKBA) could be worth
$5,955.16
+$4,955.16 (+496%) by 2050 · US Dollar
Based on the average projected AKBA price of $6.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKBAwould be worth at today's price.
$1,000 invested in AKBA on May 27, 2025 (≈ 342.465744 AKBA) would be worth
$352.74
-$647.26 (-64.7%) today · 0.35× · US Dollar
Based on a AKBA entry price of $2.92 vs. today's $1.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.01 | $1,019.8 | +2.0% |
| 1 month ago | $1.42 | $725.35 | -27.5% |
| 3 months ago | $1.32 | $780.3 | -22.0% |
| 6 months ago | $1.58 | $651.9 | -34.8% |
| 1 year ago | $2.92 | $352.74 | -64.7% |
| All time (5.0y) ago | $3.41 | $302.05 | -69.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKBA forecast.
Our base-case forecast reaches $2.10 around 2032.
Implied market cap at $2.10: $563.34M
The multi-year forecast shows a path of gradual growth, with 2026 averaging $1.02 and 2050 averaging $5.65, indicating meaningful upside over time. Sentiment is Neutral in 2026 and 2029, and Bullish in 2027, 2028, 2030-2035, 2040 and 2050. By 2031 the average is $1.68 (ROI 64.8%), by 2032 $2.03 (ROI 99.1%), by 2033 $2.15 (ROI 111.2%), by 2034 $2.26 (ROI 121.5%), and by 2035 $2.11 (ROI 106.9%).
The horizon extends to 2040 with an average of $3.67 (ROI 259.8%) and to 2050 with an average of $5.65 (ROI 454.2%). These figures are estimates and not guarantees of future results, and actual performance may vary.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.24 with a 2030 min of $0.796 and a max of $2.09, and a forecasted ROI of 21.8%. The sentiment for 2030 is Bullish.
The 2026 forecast is Neutral, with Bullish sentiment in 2027, 2028, 2030-2035, 2040 and 2050. The average price by 2050 is $5.65 and the maximum forecast is $13.00, with a long-run ROI up to 454.2%.
Yes. The 2040 forecast shows an average of $3.67 with a max of $7.68 and a Bullish sentiment, supporting the potential for prices around or above $3 by that horizon.
Current price is $1.02 and market cap is $273.62M.
Bearish sentiment with RSI14 at 40. The 30-day range is $0.7438 to $1.40, with a support at $0.895 and a resistance at $1.56.
Akebia Therapeutics, Inc. Community Discussion
0Share your Akebia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.